Neuroleptic malignant syndrome due to ziprasidone: a case report

Descripción del Articulo

Neuroleptic malignant syndrome is a rare and potentially fatal drug adverse reaction, usually associated with antipsychotics. Signs and symptoms include: fever, muscle rigidity, altered mental status and autonomic dysfunction. Laboratory findings are nonspecific, however the presence of leukocytosis...

Descripción completa

Detalles Bibliográficos
Autores: Huarcaya-Victoria, Jeff, Castillo, Claudia, Herrera, Dwight
Formato: artículo
Fecha de Publicación:2019
Institución:Universidad Peruana Cayetano Heredia
Repositorio:Revistas - Universidad Peruana Cayetano Heredia
Lenguaje:español
OAI Identifier:oai:revistas.upch.edu.pe:article/3652
Enlace del recurso:https://revistas.upch.edu.pe/index.php/RNP/article/view/3652
Nivel de acceso:acceso abierto
Materia:Neuroleptic malignant syndrome, ziprasidone, psychosis, schizophrenia.
Síndrome neuroléptico maligno, ziprasidona, psicosis, esquizofrenia.
id REVUPCH_4399d98f5f388af3a37fdb66bc0f5afb
oai_identifier_str oai:revistas.upch.edu.pe:article/3652
network_acronym_str REVUPCH
network_name_str Revistas - Universidad Peruana Cayetano Heredia
repository_id_str
spelling Neuroleptic malignant syndrome due to ziprasidone: a case reportSíndrome neuroléptico maligno debido a ziprasidona: reporte de un casoHuarcaya-Victoria, JeffCastillo, ClaudiaHerrera, DwightNeuroleptic malignant syndrome, ziprasidone, psychosis, schizophrenia.Síndrome neuroléptico maligno, ziprasidona, psicosis, esquizofrenia.Neuroleptic malignant syndrome is a rare and potentially fatal drug adverse reaction, usually associated with antipsychotics. Signs and symptoms include: fever, muscle rigidity, altered mental status and autonomic dysfunction. Laboratory findings are nonspecific, however the presence of leukocytosis and elevated creatinine phosphokinase are frequent findings. We present the case of a 51-year-old male patient from Lima with a medical history of pulmonary tuberculosis and schizophrenia that comes to our hospital with psychotic symptoms. After being treated with ziprasidone, administered by intramuscular injection presents with typical symptoms of neuroleptic malignant syndrome. Knowing the clinical features and the pathophysiology of this syndrome will allow us to better approach the condition. Due to its infrequent presentation, it may not be considered within the differential diagnosis, which could be harmful to the patient.El síndrome neuroléptico maligno es una rara y potencialmente fatal reacción adversa medicamentosa, asociada usualmente al uso de antipsicóticos. Tiene por características la presencia de fiebre, rigidez muscular, estado mental alterado y disfunción autonómica. Los hallazgos de laboratorio son inespecíficos, sin embargo, la presencia de leucocitosis y elevación de la creatina fosfoquinasason hallazgos frecuentes. Presentamos el caso de un paciente varón de 51 años, natural de Lima con antecedentes médicos de tuberculosis pulmonar y esquizofrenia que acude a nuestro hospital con un cuadro de psicosis quien, luego de ser tratado con ziprasidona administrada por vía intramuscular, presentó los síntomas característicos de un síndrome neuroléptico maligno. Conocer la clínica y la fisiopatología de este síndrome nos permitirá un mejor abordaje, ya que por su poca frecuencia podría no llegar a plantearse dentro de los diagnósticos diferenciales, lo que resultaría perjudicial para el paciente.Universidad Peruana Cayetano Heredia2019-12-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistas.upch.edu.pe/index.php/RNP/article/view/365210.20453/rnp.v82i4.3652Revista de Neuro-Psiquiatria; Vol. 82 No. 4 (2019): October - December; 298-303Revista de Neuro-Psiquiatría; Vol. 82 Núm. 4 (2019): Octubre - Diciembre; 298-303Revista de Neuro-Psiquiatria; v. 82 n. 4 (2019): Octubre - Diciembre; 298-3031609-73940034-8597reponame:Revistas - Universidad Peruana Cayetano Herediainstname:Universidad Peruana Cayetano Herediainstacron:UPCHspahttps://revistas.upch.edu.pe/index.php/RNP/article/view/3652/4052info:eu-repo/semantics/openAccessoai:revistas.upch.edu.pe:article/36522020-06-12T18:41:40Z
dc.title.none.fl_str_mv Neuroleptic malignant syndrome due to ziprasidone: a case report
Síndrome neuroléptico maligno debido a ziprasidona: reporte de un caso
title Neuroleptic malignant syndrome due to ziprasidone: a case report
spellingShingle Neuroleptic malignant syndrome due to ziprasidone: a case report
Huarcaya-Victoria, Jeff
Neuroleptic malignant syndrome, ziprasidone, psychosis, schizophrenia.
Síndrome neuroléptico maligno, ziprasidona, psicosis, esquizofrenia.
title_short Neuroleptic malignant syndrome due to ziprasidone: a case report
title_full Neuroleptic malignant syndrome due to ziprasidone: a case report
title_fullStr Neuroleptic malignant syndrome due to ziprasidone: a case report
title_full_unstemmed Neuroleptic malignant syndrome due to ziprasidone: a case report
title_sort Neuroleptic malignant syndrome due to ziprasidone: a case report
dc.creator.none.fl_str_mv Huarcaya-Victoria, Jeff
Castillo, Claudia
Herrera, Dwight
author Huarcaya-Victoria, Jeff
author_facet Huarcaya-Victoria, Jeff
Castillo, Claudia
Herrera, Dwight
author_role author
author2 Castillo, Claudia
Herrera, Dwight
author2_role author
author
dc.subject.none.fl_str_mv Neuroleptic malignant syndrome, ziprasidone, psychosis, schizophrenia.
Síndrome neuroléptico maligno, ziprasidona, psicosis, esquizofrenia.
topic Neuroleptic malignant syndrome, ziprasidone, psychosis, schizophrenia.
Síndrome neuroléptico maligno, ziprasidona, psicosis, esquizofrenia.
description Neuroleptic malignant syndrome is a rare and potentially fatal drug adverse reaction, usually associated with antipsychotics. Signs and symptoms include: fever, muscle rigidity, altered mental status and autonomic dysfunction. Laboratory findings are nonspecific, however the presence of leukocytosis and elevated creatinine phosphokinase are frequent findings. We present the case of a 51-year-old male patient from Lima with a medical history of pulmonary tuberculosis and schizophrenia that comes to our hospital with psychotic symptoms. After being treated with ziprasidone, administered by intramuscular injection presents with typical symptoms of neuroleptic malignant syndrome. Knowing the clinical features and the pathophysiology of this syndrome will allow us to better approach the condition. Due to its infrequent presentation, it may not be considered within the differential diagnosis, which could be harmful to the patient.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-20
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistas.upch.edu.pe/index.php/RNP/article/view/3652
10.20453/rnp.v82i4.3652
url https://revistas.upch.edu.pe/index.php/RNP/article/view/3652
identifier_str_mv 10.20453/rnp.v82i4.3652
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistas.upch.edu.pe/index.php/RNP/article/view/3652/4052
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Peruana Cayetano Heredia
publisher.none.fl_str_mv Universidad Peruana Cayetano Heredia
dc.source.none.fl_str_mv Revista de Neuro-Psiquiatria; Vol. 82 No. 4 (2019): October - December; 298-303
Revista de Neuro-Psiquiatría; Vol. 82 Núm. 4 (2019): Octubre - Diciembre; 298-303
Revista de Neuro-Psiquiatria; v. 82 n. 4 (2019): Octubre - Diciembre; 298-303
1609-7394
0034-8597
reponame:Revistas - Universidad Peruana Cayetano Heredia
instname:Universidad Peruana Cayetano Heredia
instacron:UPCH
instname_str Universidad Peruana Cayetano Heredia
instacron_str UPCH
institution UPCH
reponame_str Revistas - Universidad Peruana Cayetano Heredia
collection Revistas - Universidad Peruana Cayetano Heredia
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1844250389201813504
score 12.811179
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).